FDA Drug Recalls

Recalls / Class III

Class IIID-0049-2015

Product

Carbamazepine Tablets USP, 200 mg, 1000 Tablets per Bottle, Rx only, Manufactured by: Taro Pharmaceutical Industries Ltd. Haifa Bay, Israel 26110 Distributed by: Taro Pharmaceuticals U.S.A., Inc. Hawthorne, NY 10532, NDC 51672-4005-3.

Brand name
Carbamazepine
Generic name
Carbamazepine
Active ingredient
Carbamazepine
Route
Oral
NDCs
51672-4005, 51672-4041, 51672-4050, 51672-4123, 51672-4124, 51672-4125, 51672-4047
FDA application
ANDA074649
Affected lot / code info
Lot 137393, exp. 10/2016

Why it was recalled

Marketed without an Approved NDA/ANDA: One lot was on hold-pending release status when it was erroneously made available for sale in the inventory control system. An alternate manufacturing site for the Carbamazepine API final intermediate was pending approval.

Recalling firm

Firm
Taro Pharmaceuticals U.S.A., Inc.
Manufacturer
Sun Pharmaceutical Industries, Inc.
Notification channel
Letter
Type
Voluntary: Firm initiated
Address
3 Skyline Dr, N/A, Hawthorne, New York 10532-2174

Distribution

Quantity
1,966 bottles
Distribution pattern
IL, OH, LA

Timeline

Recall initiated
2014-10-21
FDA classified
2014-10-27
Posted by FDA
2014-11-05
Terminated
2017-04-03
Status
Terminated

Source: openFDA Drug Enforcement endpoint. Recall record D-0049-2015. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.

Class III recall: Carbamazepine · FDA Drug Recalls